Hormone Insight

Is 3 months of romosozumab noninferior to 12 months for increasing hip BMD in postmenopausal osteoporosis?

In postmenopausal women at high fracture risk, 3 months of romosozumab followed by 9 months of denosumab was non-inferior to 12 months of romosozumab for increasing total hip BMD over 12 months.

Randomised trial · Lancet Diabetes & Endocrinology 2026

Reference: Leder BZ, Ramchand SK, Jordan M, et al. Lancet Diabetes Endocrinol. 2026;14(3):216-222. PMID:41621431. https://pubmed.ncbi.nlm.nih.gov/41621431/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Can surgery treat arterial hypertension in patients with unilateral adrenal incidentalomas and mild autonomous cortisol secretion?

In patients with hypertension and mild autonomous cortisol secretion from a unilateral adrenal incidentaloma, adrenalectomy improved blood pressure control more than conservative management.

Randomised trial · Lancet Diabetes & Endocrinology 2025

Reference: Tabarin A, Espiard S, Deutschbein T, et al. CHIRACIC: adrenalectomy versus conservative management in patients with unilateral adrenal incidentaloma and mild autonomous cortisol secretion. Lancet Diabetes Endocrinol. 2025. DOI:10.1016/S2213-8587(25)00062-2. PMID:40373786. https://pubmed.ncbi.nlm.nih.gov/40373786/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Was testosterone replacement non-inferior to placebo for cardiovascular safety in men with hypogonadism and high cardiovascular risk?

In TRAVERSE, testosterone replacement was non-inferior to placebo for major adverse cardiac events in middle-aged and older men with hypogonadism and high cardiovascular risk.

Randomised trial · New England Journal of Medicine 2023

Reference: Lincoff AM, Bhasin S, Flevaris P, et al. N Engl J Med. 2023;389(2):107-117. PMID: 37326322. https://pubmed.ncbi.nlm.nih.gov/37326322/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Which statin side effects are supported by blinded trials?

Blinded-trial evidence supported increased liver-test abnormalities but did not show excess risk for most other outcomes attributed to statins in product labels. Previously established muscle and diabetes risks remain clinically relevant.

This episode discusses a meta-analysis, not a single randomised trial.

Reference: Cholesterol Treatment Trialists’ (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet. 2026;407(10529):689–703. doi:10.1016/S0140-6736(25)01578-8. PMID:41655587.

Chapters

0:00 Introduction

0:38 The evidence

3:11 Interpretation

3:48 Outro

Read the structured summary at https://hormoneinsight.com

AI narration is used. This podcast is intended for healthcare professionals and is educational, not medical advice. Views are the presenter’s own and do not necessarily reflect those of any institution with which he works.

Hormone Insight: https://hormoneinsight.com

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does bempedoic acid reduce cardiovascular events in statin-intolerant patients?

In CLEAR Outcomes, bempedoic acid lowered LDL cholesterol and reduced major adverse cardiovascular events versus placebo.

Randomised trial · New England Journal of Medicine 2023

Reference: Nissen SE, Lincoff AM, Brennan D, et al. N Engl J Med. 2023;388(15):1353-1364. PMID: 36876740. https://pubmed.ncbi.nlm.nih.gov/36876740/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Can levothyroxine be discontinued in older adults with subclinical hypothyroidism?

In a pilot randomised trial, stopping low-dose levothyroxine did not change hypothyroid symptoms, tiredness or quality of life over six months compared with continuing treatment.

Pilot randomised trial · Endocrine 2025

Reference: Maraka S, et al. Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomised clinical trial. Endocrine. 2025;90(2):781-792. doi:10.1007/s12020-025-04371-z. PMID: 40736623. https://pubmed.ncbi.nlm.nih.gov/40736623/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Is secukinumab effective for active, moderate-to-severe Graves orbitopathy?

In a randomised trial, secukinumab did not improve clinical response compared with placebo at 16 weeks.

Randomised trial · Journal of Clinical Endocrinology & Metabolism 2026

Reference: Wolf J, et al. Secukinumab in moderate-to-severe Graves orbitopathy: a randomised, double-blind, placebo-controlled multicentre study. J Clin Endocrinol Metab. 2026;111(5):1248-1257. doi:10.1210/clinem/dgaf655. PMID: 41362233. https://pubmed.ncbi.nlm.nih.gov/41362233/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does selenium supplementation benefit people with newly diagnosed Graves' hyperthyroidism?

In the GRASS randomised trial, selenium did not improve remission rates or quality of life compared with placebo.

Randomised trial · European Thyroid Journal 2026

Reference: Cramon P, et al. Selenium supplementation in individuals with newly diagnosed Graves' hyperthyroidism: a double-blind, multicentre RCT. Eur Thyroid J. 2026;15(1). doi:10.1530/ETJ-25-0264. PMID: 41384622. https://pubmed.ncbi.nlm.nih.gov/41384622/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

What happens at 5 years of follow-up with thyroidectomy without radioiodine in patients with low-risk thyroid cancer?

In patients with low-risk differentiated thyroid cancer, a follow-up strategy without radioiodine was non-inferior to postoperative radioiodine at 5 years.

Randomized trial · Lancet Diabetes Endocrinol 2025

Reference: Leboulleux. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial. The Lancet Diabetes & Endocrinology. 2025;13(1):38–46. doi:10.1016/S2213-8587(24)00276-6. PMID:39586309.

Chapters

0:00 Intro

0:38 The trial

3:19 My take

3:50 Outro

Read the structured trial summary at https://hormoneinsight.com

AI narration is used. This podcast is intended for healthcare professionals only. It is educational, not medical advice. Views expressed are the presenter’s own and do not necessarily reflect those of any institution he works with.

Hormone Insight: https://hormoneinsight.com

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

After thyroidectomy for low-risk differentiated thyroid cancer, is omission of postoperative radioiodine non-inferior to ablation?

In the IoN randomised trial, omission of postoperative radioiodine was noninferior to ablation for 5-year recurrence-free survival.

Randomised multicentre non-inferiority trial · The Lancet 2025

Reference: Mallick U, et al. Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN). Lancet. 2025;406(10498):52-62. doi:10.1016/S0140-6736(25)00629-4. PMID: 40543520. https://pubmed.ncbi.nlm.nih.gov/40543520/

This is a summary of trial findings, not an individual treatment recommendation.

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en